Biotech · Public company · Frederick, MD, US
Cartesian Therapeutics, Inc.
Ticker RNAC · SEC CIK 0001453687
Track this companyFree. Adds Cartesian Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials125 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- Decartes-08Phase 3 · Myasthaenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- Descartes 08Phase 2 · Myeloma MultipleClinicalTrials.gov · fetched Nov 12, 2026
- Descartes 11Phase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-08Phase 2 · Myasthenia Gravis, GeneralizedClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-08Phase 2 · Childhood-onset Systemic Lupus ErythematousClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-08Phase 2 · Antisynthetase SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-08Phase 2 · Systemic Lupus Erythematosus (SLE)ClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Descartes 30Phase 1 · Acute Respiratory Distress SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-08Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-15Phase 1 · Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Descartes-25Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- Descartes-08 in Autoantibody MyositisPHASE2 · RECRUITING · started Apr 28, 2026ClinicalTrials.gov NCT07391605 · fetched Nov 12, 2026
- Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersPHASE1_PHASE2 · RECRUITING · started Jan 14, 2026ClinicalTrials.gov NCT07089121 · fetched Nov 12, 2026
- Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisPHASE3 · ACTIVE_NOT_RECRUITING · started May 6, 2025ClinicalTrials.gov NCT06799247 · fetched Nov 12, 2026
- Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaPHASE1 · TERMINATED · started Jun 19, 2024ClinicalTrials.gov NCT06304636 · fetched Nov 12, 2026
- Descartes-08 for Patients With Systemic Lupus ErythematosusPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 12, 2024ClinicalTrials.gov NCT06038474 · fetched Nov 12, 2026
- Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyPHASE2 · TERMINATED · started Dec 1, 2021ClinicalTrials.gov NCT04816526 · fetched Nov 12, 2026
- Descartes-25 in Relapsed/Refractory Multiple MyelomaPHASE1 · TERMINATED · started Nov 25, 2021ClinicalTrials.gov NCT05113342 · fetched Nov 12, 2026
- Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyPHASE2 · COMPLETED · started Feb 24, 2021ClinicalTrials.gov NCT04436029 · fetched Nov 12, 2026
- Study of Descartes-30 in Acute Respiratory Distress SyndromePHASE1 · TERMINATED · started Feb 23, 2021ClinicalTrials.gov NCT04524962 · fetched Nov 12, 2026
- Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 4, 2019ClinicalTrials.gov NCT04146051 · fetched Nov 12, 2026
- Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaPHASE1 · TERMINATED · started Aug 1, 2019ClinicalTrials.gov NCT03994705 · fetched Nov 12, 2026
- Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaPHASE1 · TERMINATED · started Mar 8, 2018ClinicalTrials.gov NCT03448978 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 9, 2026 · fetched Nov 12, 2026
NIH awards3
- Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)Fiscal year 2025 · $1.5MNIH RePORTER 5R44NS137943-02 · fetched Nov 12, 2026
- Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)Fiscal year 2024 · $1.5MNIH RePORTER 1R44NS137943-01 · fetched Nov 12, 2026
- Targeting BCMA+ Cells with RNA-engineered CAR T cells to treat Lupus: A Phase 2 clinical studyFiscal year 2024 · $149KNIH RePORTER 1U44AI184200-01 · fetched Nov 12, 2026